Tejas Patil

3.3k total citations
67 papers, 836 citations indexed

About

Tejas Patil is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Tejas Patil has authored 67 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pulmonary and Respiratory Medicine, 51 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Tejas Patil's work include Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (22 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Tejas Patil is often cited by papers focused on Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (22 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Tejas Patil collaborates with scholars based in United States, Canada and Japan. Tejas Patil's co-authors include D. Ross Camidge, Robert C. Doebele, Paul A. Bunn, Dara L. Aisner, W. Thomas Purcell, Daniel W. Bowles, Derek Smith, Anh T. Le, Mark J. Hancock and Erin L. Schenk and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Tejas Patil

62 papers receiving 819 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tejas Patil United States 16 624 544 228 161 66 67 836
Yun Fan China 16 467 0.7× 446 0.8× 223 1.0× 176 1.1× 74 1.1× 44 721
Reiko Kaji Japan 20 1.0k 1.6× 793 1.5× 236 1.0× 249 1.5× 65 1.0× 44 1.2k
Sehhoon Park South Korea 18 601 1.0× 543 1.0× 203 0.9× 229 1.4× 95 1.4× 68 895
Lilia Stelmakh Russia 4 1.1k 1.7× 935 1.7× 226 1.0× 159 1.0× 60 0.9× 8 1.2k
Anna Wrona Poland 12 519 0.8× 449 0.8× 180 0.8× 96 0.6× 34 0.5× 34 692
Bethany Pitcher Canada 16 402 0.6× 516 0.9× 337 1.5× 237 1.5× 79 1.2× 27 832
Pierpaolo Camplese Italy 8 815 1.3× 627 1.2× 273 1.2× 229 1.4× 85 1.3× 17 988
Janice F. Eakle United States 9 345 0.6× 565 1.0× 246 1.1× 265 1.6× 60 0.9× 22 805
Tahsin M. Khan United States 8 364 0.6× 344 0.6× 275 1.2× 115 0.7× 51 0.8× 23 604

Countries citing papers authored by Tejas Patil

Since Specialization
Citations

This map shows the geographic impact of Tejas Patil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tejas Patil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tejas Patil more than expected).

Fields of papers citing papers by Tejas Patil

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tejas Patil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tejas Patil. The network helps show where Tejas Patil may publish in the future.

Co-authorship network of co-authors of Tejas Patil

This figure shows the co-authorship network connecting the top 25 collaborators of Tejas Patil. A scholar is included among the top collaborators of Tejas Patil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tejas Patil. Tejas Patil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gerber, David E., Tanushree Prasad, Song Zhang, et al.. (2025). Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials. Clinical Cancer Research. 31(6). 1103–1108. 1 indexed citations
2.
Baik, Christina S., Christine M. Lovly, Tejas Patil, et al.. (2024). PP01.115 Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Mutations. Journal of Thoracic Oncology. 19(7). e49–e50. 1 indexed citations
3.
4.
5.
Tsui, David Chun Cheong, Douglas E. Holt, Tejas Patil, et al.. (2024). The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer. Advances in Radiation Oncology. 9(7). 101516–101516. 2 indexed citations
6.
Muro, Kei, Trevor Feinstein, Joaquina Baranda, et al.. (2024). Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202.. Journal of Clinical Oncology. 42(16_suppl). 8585–8585. 2 indexed citations
7.
Sun, Lova, Joshua E. Reuss, Geoffrey Liu, et al.. (2023). P2.31-05 Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data. Journal of Thoracic Oncology. 18(11). S408–S409.
8.
Drilon, Alexander, Lin Shen, François Doz, et al.. (2023). 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer. Annals of Oncology. 34. S470–S470. 2 indexed citations
9.
Iams, Wade T., Sharon Phillips, Adrian G. Sacher, et al.. (2023). A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer. Clinical Lung Cancer. 24(3). 228–234. 2 indexed citations
10.
Marmarelis, Melina E., Caroline E. McCoach, Geoffrey Liu, et al.. (2023). Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9116–9116.
11.
Patil, Tejas, et al.. (2023). Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance. npj Precision Oncology. 7(1). 56–56. 6 indexed citations
12.
Patil, Tejas, D. Ross Camidge, Paul A. Bunn, et al.. (2023). CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 178. 103–107. 7 indexed citations
13.
Patil, Tejas, et al.. (2019). Enhancing Image Security by employing Blowfish Algorithm further embedding text and Stitching the RGB components of a Host Image. International Journal of Recent Technology and Engineering (IJRTE). 8(2S11). 3801–3808. 1 indexed citations
14.
Patil, Tejas, et al.. (2019). Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs of today. 55(10). 641–641. 20 indexed citations
15.
Patil, Tejas, Derek Smith, Paul A. Bunn, et al.. (2018). The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. Journal of Thoracic Oncology. 13(11). 1717–1726. 138 indexed citations
16.
Patil, Tejas, Danielle Smith, Paul A. Bunn, et al.. (2018). P1.01-78 The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib. Journal of Thoracic Oncology. 13(10). S492–S493.
17.
Ng, Terry L., Rustain Morgan, Tejas Patil, et al.. (2018). Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. Lung Cancer. 126. 112–118. 13 indexed citations
18.
Noonan, Sinéad, Tejas Patil, Dexiang Gao, et al.. (2017). Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. Journal of Thoracic Oncology. 13(1). 134–138. 19 indexed citations
19.
Patil, Tejas, et al.. (2017). Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer. 109. 28–35. 12 indexed citations
20.
Mahimkar, Manoj B., et al.. (2010). Influence of genetic polymorphisms on frequency of micronucleated buccal epithelial cells in leukoplakia patients. Oral Oncology. 46(10). 761–766. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yun Fan Breakdown of academic impact, for papers by Reiko Kaji Breakdown of academic impact, for papers by Sehhoon Park Breakdown of academic impact, for papers by Lilia Stelmakh Breakdown of academic impact, for papers by Anna Wrona Breakdown of academic impact, for papers by Bethany Pitcher Breakdown of academic impact, for papers by Pierpaolo Camplese Breakdown of academic impact, for papers by Janice F. Eakle Breakdown of academic impact, for papers by Tahsin M. Khan
Rankless by CCL
2026